**Supplementary Table 3. Hazard of Death**a,b

|  |  |  |
| --- | --- | --- |
|  | **Acute Lymphoblastic Leukemia** | **Acute Myeloid Leukemia** |
|  | HR d (95% CI) | p-value | HR (95% CI) | p-value |
| **Gender** |  |  |  |  |
| Male | 1.0 (0.8-1.3) | 0.8 | 1.2 (0.9-1.6) | 0.2 |
| **Race/Ethnicity** |
| **Non-Hispanic White** | 1.0 | - | 1.0 | - |
| **African-American/Hispanic** | 1.5 (1.0-2.3) | 0.06 | 1.2 (0.8-1.7) | 0.4 |
| **Asian-Pacific Islander** | 0.7 (0.3-1.5) | 0.7 | 1.0 (0.6-1.7) | 1.0 |
| **Socioeconomic Status (SES)** |
| **High SES** | 1.0 | - | 1.0 | - |
| **Middle SES** | 0.8 (0.5-1.3) | 0.3 | 1.4 (0.9-2.4) | 0.2 |
| **Low SES** | 1.0 (0.6-1.7) | 0.9 | 1.3 (0.7-2.3) | 0.4 |
| **Payor** |
| **Private Insurance** | 1.0 | - | 1.0 | - |
| **Public/No Insurance** | 1.0 (0.8-1.4) | 0.7 | 1.1 (0.8-1.5) | 0.5 |

aThis table presents additional findings from multivariable Cox regression analysis as presented in Table 3, including 1-39y patients with AML and 10-39y ALL patients. The results above are also adjusted for age and CCC/COG vs. Non-CCC/COG

bNS = not statistically significant